Gaviscon Liquid Aniseed Flavour
*Company:
Reckitt Benckiser Ireland LimitedStatus:
No Recent UpdateLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 14 September 2021
File name
Gaviscon Liquid Aniseed PIL.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 13 May 2021
File name
Gaviscon Liquid Aniseed Flavour SmPC May21.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Supply through general sale
Updated on 15 January 2020
File name
Gaviscon Liquid Aniseed Flavour.pdf
Reasons for updating
- New PIL for new product
Updated on 14 June 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Updated on 14 June 2016
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
100ml bottle size has been removed from Section 4.1 and section 4.2 of SmPC
Updated on 14 June 2016
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
Free text change information supplied by the pharmaceutical company
100ml bottle size has been removed from Section 4.1 and section 4.2 of SmPC
Updated on 19 April 2016
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 6.5 - 100ml bottle size has been deleted
Updated on 19 April 2016
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
Section 6.5 - 100ml bottle size has been deleted
Updated on 08 September 2014
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
In section 4.2 - The format has changed. Additional information has been added regarding special patient groups. Added that the clinical situation should be reviewed after 7 days.
Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.
Section 4.5 - Added a time interval between taking Gaviscon and other products.
Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility
Section 4.7 - Changed wording.
Section 4.8 - The format has changed. Added information on how to report suspected adverse events.
Section 10 - Updated the date of revision of the text.
Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.
Section 4.5 - Added a time interval between taking Gaviscon and other products.
Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility
Section 4.7 - Changed wording.
Section 4.8 - The format has changed. Added information on how to report suspected adverse events.
Section 10 - Updated the date of revision of the text.
Updated on 08 September 2014
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.2 - The format has changed. Additional information has been added regarding special patient groups. Added that the clinical situation should be reviewed after 7 days.
Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.
Section 4.5 - Added a time interval between taking Gaviscon and other products.
Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility
Section 4.7 - Changed wording.
Section 4.8 - The format has changed. Added information on how to report suspected adverse events.
Section 10 - Updated the date of revision of the text.
Section 4.4 - Added that if symptoms persist after 7 days to consult a doctor. Added additional warnings regarding excipients.
Section 4.5 - Added a time interval between taking Gaviscon and other products.
Section 4.6 - Added specific information to each category Pregnancy, Breast-feeding, and Fertility
Section 4.7 - Changed wording.
Section 4.8 - The format has changed. Added information on how to report suspected adverse events.
Section 10 - Updated the date of revision of the text.
Updated on 13 December 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
In section 4.4, added "Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed)".
Updated on 13 December 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Free text change information supplied by the pharmaceutical company
In section 4.4, added "Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed)".
Updated on 15 May 2007
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
SECTION 2. Qualitative and Quantitative Composition expanded to include the concentration of sodium and parahydroxybenzoate per 10ml dose
SECTION 4.3. Contraindications now includes a statement on hypersensitivity to any of the ingredients.
SECTION 4.8. Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions
SECTION 7. Change of address of marketing authorisation holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
Updated on 15 May 2007
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
SECTION 2. Qualitative and Quantitative Composition expanded to include the concentration of sodium and parahydroxybenzoate per 10ml dose
SECTION 4.3. Contraindications now includes a statement on hypersensitivity to any of the ingredients.
SECTION 4.8. Allergic manifestations expanded to include anaphylactic and anaphylactoid reactions
SECTION 7. Change of address of marketing authorisation holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
Updated on 09 August 2006
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5. Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.
Reduction in shelf-life from three years to two years in section 6.3
Updated on 09 August 2006
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
Free text change information supplied by the pharmaceutical company
Changes to pack sizes in sections 4.1, 4.2, 4.4 and 6.5. Pack sizes of 200 and 300ml have been removed from the sections denoting packs for retail sale through pharmacies only and a 300 ml pack has been added to the sections denoting packs for general sale.
Reduction in shelf-life from three years to two years in section 6.3
Updated on 19 May 2005
Reasons for updating
- Improved electronic presentation
Legal category:Supply through general sale
Updated on 19 May 2005
Reasons for updating
- Improved electronic presentation
Updated on 10 August 2004
Reasons for updating
- Improved electronic presentation
Legal category:Supply through general sale
Updated on 10 August 2004
Reasons for updating
- Improved electronic presentation
Updated on 20 August 2003
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
Legal category:Supply through general sale
Updated on 20 August 2003
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
Updated on 16 June 2003
Reasons for updating
- New SPC for medicines.ie
Legal category:Supply through general sale
Updated on 16 June 2003
Reasons for updating
- New SPC for medicines.ie